Also trades as: 4582.T (JPX) · $vol 0M
SYMQY OTC
SymBio Pharmaceuticals Limited
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: -12.4%
1Y: -41.5%
3Y: -92.0%
5Y: -77.2%
$0.56
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$3.9B
-22.1% ▼
5Y CAGR: -9.2%
Total Liabilities
$2.6B
+236.9% ▲
5Y CAGR: +9.9%
Shareholders Equity
$1.3B
-69.7% ▼
5Y CAGR: -22.9%
Cash & Investments
$2.9B
-27.2% ▼
5Y CAGR: -5.6%
Total Debt
$2.0B
+0.0% ▲
Net Debt
-$902M
+77.3% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $3.9B | $6.3B | $6.5B | $4.0B | $2.9B |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash & ST Investments | $3.9B | $6.3B | $6.5B | $4.0B | $2.9B |
| Net Receivables | $2.1B | $2.1B | $30K | $423M | $260M |
| Inventory | $386M | $469M | $232M | $239M | $289M |
| Other Current Assets | $17M | $13M | $943M | $73M | $72M |
| Total Current Assets | $6.7B | $9.3B | $8.1B | $4.9B | $3.8B |
| Property, Plant & Equip. | $170M | $154M | $88M | $44M | $0 |
| Goodwill & Intangibles | $259M | $222M | $0 | $0 | $0 |
| Long-Term Investments | -$87M | $85M | $87M | $0 | $15K |
| Other Non-Current Assets | $87M | -$85M | -$87M | $0 | $37M |
| Total Non-Current Assets | $1.7B | $1.1B | $88M | $44M | $43M |
| Total Assets | $8.5B | $10.4B | $8.2B | $5.0B | $3.9B |
| — Liabilities — | |||||
| Accounts Payable | $70M | $47M | $0 | $0 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 | $683M |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $34M | $312M | $84M | $28M | $490M |
| Total Current Liabilities | $1.5B | $1.9B | $957M | $766M | $1.3B |
| Long-Term Debt | $0 | $0 | $0 | $0 | $1.3B |
| Other Non-Current Liab. | $189M | $3M | $4M | $5M | $5M |
| Total Non-Current Liabilities | $189M | $3M | $4M | $5M | $1.3B |
| Total Liabilities | $1.7B | $1.9B | $960M | $771M | $2.6B |
| — Equity — | |||||
| Common Stock | $17.2B | $17.5B | $18.0B | $18.3B | $19.3B |
| Retained Earnings | -$28.0B | -$26.9B | -$28.9B | -$32.7B | -$37.5B |
| Accumulated OCI | $519M | $412M | $0 | $0 | $361M |
| Total Stockholders Equity | $6.7B | $8.5B | $7.2B | $4.2B | $1.3B |
| Total Liabilities & Equity | $8.5B | $10.4B | $8.2B | $5.0B | $3.9B |
| — Key Metrics — | |||||
| Total Debt | $0 | $0 | $0 | $0 | $2.0B |
| Net Debt | -$3.9B | -$6.3B | -$6.5B | -$4.0B | -$902M |
| Total Investments | -$87M | $85M | $87M | $0 | $15K |